Online Program Home
My Program

CC = Vancouver Convention Centre   F = Fairmont Waterfront Vancouver
* = applied session       ! = JSM meeting theme

Activity Details

674 ! Thu, 8/2/2018, 10:30 AM - 12:20 PM CC-West 119
Adaptive Design - 3 — Contributed Papers
Biopharmaceutical Section
Chair(s): Ying Grace Li, Eli Lilly and Company
10:35 AM A Bayesian Adaptive Phase 1/2 Design of Cisplatin and Cabazitaxel in Prostate Cancer with Visceral Metastasis

Mourad Tighiouart, Cedars-Sinai Medical Center
10:50 AM Adaptive Bayesian Interval-Based Oncology Dose Finding Design with Quasi-Continuous Toxicity Model

Dan Zhao, University of Illinois at Chicago; Jian Zhu, Takeda; Eric Westin, ImmunoGen; Ling Wang, Takeda
11:05 AM Bias-Corrected Estimation of Treatment Effects in Biomarker-Based Adaptive Subgroup Analysis: New Approach Based on Randomized Tests with Smooth Rejection Function

Kiichiro Toyoizumi, Shionogi Inc.; Shigeyuki Matsui, Nagoya University
11:20 AM Practical Considerations of Subgroups Quantification, Selection and Adaptive Enrichment in Confirmatory Trials

Jianchang Lin, Takeda Pharmaceuticals; Rachael Liu, Takeda Pharmaceuticals ; Veronica Bunn, Florida State University
11:35 AM An Adaptive Dose Selection Case Study: Statistical Methods and Operational Considerations

Adam Hamm, Cytel, Inc.
11:50 AM Statistical Monitoring of Semi-Competing Risk Outcomes in Clinical Trials

Toshi Hamasaki; Scott Evans, Harvard University; Tomoyuki Sugimoto, Kagoshima University; Koko Asakura, National Cerebral and Cardiovascular Center; Susan Halabi, Duke University
12:05 PM BOIN-ET: Bayesian Optimal Interval Design for Dose Finding Based on Both Efficacy and Toxicity Outcomes

Kentaro Takeda, Astellas Pharma Global Development, Inc.; Masataka Taguri, Yokohama City University; Satoshi Morita, Kyoto University